| Original language | English (US) |
|---|---|
| Pages (from-to) | 1426-1428 |
| Number of pages | 3 |
| Journal | JAMA Oncology |
| Volume | 4 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2018 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Financial Conflicts of Interest among Oncologist Authors of Reports of Clinical Drug Trials. / Wayant, Cole; Turner, Erick; Meyer, Chase; Sinnett, Philip; Vassar, Matt.
In: JAMA Oncology, Vol. 4, No. 10, 10.2018, p. 1426-1428.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Financial Conflicts of Interest among Oncologist Authors of Reports of Clinical Drug Trials
AU - Wayant, Cole
AU - Turner, Erick
AU - Meyer, Chase
AU - Sinnett, Philip
AU - Vassar, Matt
N1 - Funding Information: Published Online: August 23, 2018. doi:10.1001/jamaoncol.2018.3495 Author Contributions: Dr Hillen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Hillen, Smets, van Laarhoven, Sommeijer. Acquisition, analysis, or interpretation of data: Hillen, Woei-A-Jin, van Maarschalkerweerd, van Laarhoven, Sommeijer. Drafting of the manuscript: Hillen, Sommeijer. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Hillen. Obtained funding: Hillen. Administrative, technical, or material support: Hillen, Sommeijer. Supervision: Woei-A-Jin, Smets, van Laarhoven. Coding data: van Maarschalkerweerd. Conflict of Interest Disclosures: Dr van Laarhoven reported serving in a consulting or advisory role for Eli Lilly and Company and Nordic Pharma and receiving research funding from Bayer, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly and Company, Nordic Pharma, Philips, and Hoffmann-La Roche. No other disclosures were reported. Funding/Support: Financial support for this study was provided by grant UVA 2014-6671 from the Dutch Cancer Society (KWF Kankerbestrijding) (Dr Hillen). Copyright: Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2018/10
Y1 - 2018/10
UR - http://www.scopus.com/inward/record.url?scp=85053046792&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053046792&partnerID=8YFLogxK
U2 - 10.1001/jamaoncol.2018.3738
DO - 10.1001/jamaoncol.2018.3738
M3 - Letter
C2 - 30178024
AN - SCOPUS:85053046792
VL - 4
SP - 1426
EP - 1428
JO - JAMA oncology
JF - JAMA oncology
SN - 2374-2437
IS - 10
ER -